OLEMA PHARMACEUTICALS, INC. Capital Expenditures
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Capital Expenditures of $221.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $6.00K.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $159.00K.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $363.00K, a 76.95% decline from fiscal 2021.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $1.57M, a 2712.50% increase from fiscal 2020.
- OLEMA PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2020 was $56.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $221.00K 10-Q · filed 2026-08-10 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $6.00K derived: sum of 3 quarters · filed 2026-03-16 | $159.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $6.00K derived: sum of 2 quarters · filed 2025-11-10 | $159.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $159.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $153.00K 10-Q · filed 2025-05-13 | |||
| 2022-12-31 | $173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $312.00K derived: sum of 2 quarters · filed 2024-03-11 | $333.00K derived: sum of 3 quarters · filed 2024-03-11 | $363.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $160.00K derived: sum of 2 quarters · filed 2023-11-07 | $190.00K 10-Q · filed 2023-11-07 | $889.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $51.00K 10-Q · filed 2023-08-08 | $750.00K derived: sum of 3 quarters · filed 2023-08-08 | $846.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $30.00K 10-Q · filed 2023-05-09 | $729.00K derived: sum of 2 quarters · filed 2023-05-09 | $825.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.19M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $795.00K derived: sum of 2 quarters · filed 2023-03-09 | $1.16M derived: sum of 3 quarters · filed 2023-03-09 | $1.57M 10-K · filed 2023-03-09 |
| 2021-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $456.00K derived: sum of 2 quarters · filed 2022-11-08 | $876.00K 10-Q · filed 2022-11-08 | $927.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $780.00K 10-Q · filed 2022-08-09 | $831.00K derived: sum of 3 quarters · filed 2022-08-09 | $821.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $420.00K 10-Q · filed 2022-05-09 | $471.00K derived: sum of 2 quarters · filed 2022-05-09 | $461.00K derived: sum of 3 quarters · filed 2022-05-09 | $467.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $41.00K derived: sum of 2 quarters · filed 2022-02-28 | $47.00K derived: sum of 3 quarters · filed 2022-02-28 | $56.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$4.00K derived: sum of 2 quarters · filed 2021-11-10 | $5.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $15.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $9.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |